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Abstract The voluntary withdrawal of Vioxx (rofecoxib)
from the market in 2004, as well as the 2005 and 2014 US
FDA Advisory Committee meetings about non-steroidal
anti-inflammatory drugs (NSAIDs) and cardiovascular risk,
have raised questions surrounding the use of NSAIDs in at-
risk populations. This paper discusses the cardiovascular
safety profile of naproxen in the context of the NSAID
class. The balance of evidence suggests that cardiovascular
risk correlates with cyclooxygenase (COX)-2 selectivity,
and the low COX-2 selectivity of naproxen results in a
lower cardiovascular risk than that of other NSAIDs. The
over-the-counter (OTC) use of naproxen is expected to
pose minimal cardiovascular risk; however, the benefit–
risk ratio and appropriate use should be considered at an
individual patient level, particularly to assess underlying
conditions that may increase the risk of events. Likewise,
regulatory authorities should revisit label information
periodically to ensure labeling reflects the current under-
standing of benefits and risks.
Key Points
The totality of evidence suggests that while non-
steroidal anti-inflammatory drugs (NSAIDs) likely
increase the risk of cardiovascular events, they do so
based on cyclooxygenase (COX)-2 selectivity,
with greater affinity for COX-2 imparting greater
risk.
Naproxen has low COX-2 selectivity, instead
demonstrating greater selectivity for COX-1
inhibition, imparting a consistent and demonstrably
favorable thromboembolic and overall
cardiovascular safety profile among the most
commonly used non-aspirin NSAIDs.
1 Introduction
1.1 Non-Steroidal Anti-Inflammatory Drug
(NSAID) Background
1.1.1 Therapeutic Importance
Musculoskeletal aches and pains are one of the most
common medical complaints around the world, and
increasing life expectancies are driving an increased inci-
dence of degenerative joint disease, burdening patients and
healthcare systems [1]. Non-steroidal anti-inflammatory
drugs (NSAIDs) are the most commonly used class of
analgesic drugs, with approximately 30 million users
worldwide daily [2] and over 100 million prescriptions
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every year in the USA [3]. NSAIDs continue to be one of
the most effective and widely used forms of non-surgical
pain relief for osteoarthritis [1]. A significant portion of the
population appropriately manages pain with over-the-
counter (OTC) NSAIDs [4]. In contrast, other prescription
pain relievers (e.g., opioids) lend themselves to abuse,
which has become a growing epidemic [5].
1.1.2 Regulatory Interest
The widespread use of NSAIDs means there is significant
regulatory interest in this therapeutic category. Further-
more, after the voluntary withdrawal of Vioxx (rofecoxib)
in 2004, regulatory authorities have focused on potential
adverse cardiovascular outcomes.
The US FDA Advisory Committee meetings in both
2005 and 2014 concluded that NSAIDs increased the risk
of myocardial infarction (MI) in high-risk individuals, and
they supported the need for additional label warnings and
studies to further clarify whether the increased risk was
truly a class effect or the result of cyclooxygenase (COX)-2
selectivity. The 2005 meeting resulted in changes to the
label for all NSAIDs, including OTC NSAIDs, to highlight
this risk [6–8].
The 2014 FDA Advisory Committee meeting on the
cardiovascular risk of NSAIDs included an FDA review of
data available after 2005, highlighting a potential lower
cardiovascular risk with naproxen than with other NSAIDs,
as well as a discussion of the progress of PRECISION
(Prospective Randomized Evaluation of Celecoxib Inte-
grated Safety versus Ibuprofen Or Naproxen), an ongoing
cardiovascular safety study [9]. The committee reaffirmed
the position that class labeling was appropriate and should
not differentiate between products, forms, and dose (in-
cluding for OTC medications). Nonetheless, many of the
committee members expressed the view that the data sug-
gest a more favorable cardiovascular risk profile for
naproxen than for other NSAIDs, even if it did not meet the
evidentiary standard for supporting a regulatory label
change. Furthermore, risk may be mitigated through low
doses or a shorter duration of use, such as that with OTC
naproxen. In addition, numerous other regulatory bodies
have contributed to NSAID safety, with ingredient-specific
differences in recommendations by country. For instance,
in the UK, diclofenac was switched back from OTC to
prescription status based on safety concerns, and the
European Medicines Agency (EMA) determined that
naproxen ‘‘may be associated with a lower risk for arterial
thrombotic events than COX-2 inhibitors and other
NSAIDs, but a small risk cannot be excluded’’ [10].
We review the totality of evidence regarding naproxen




Naproxen has been available as a prescription product in
the USA since 1976, and naproxen sodium has been
approved for OTC use in many countries. Non-prescription
dosing is appropriate every 8–12 h, with a maximum total
daily OTC dose of 440–660 mg, as approved by local
regulatory authorities. This differs from the prescription
Fig. 1 Non-steroidal anti-inflammatory drug cyclooxygenase selec-
tivity and half-life. Adapted from Goodman and Gilman [19]. COX
cyclooxygenase, NSAID non-steroidal anti-inflammatory drug
Fig. 2 Odds ratios and 95 % confidence intervals for cardiovascular
death based on non-steroidal anti-inflammatory drug (NSAID) dose.
Odds ratios for cardiovascular death (composite endpoint of death or
myocardial infarction) in association with NSAID exposure Data
from Fosbøl et al. [98]
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dosing regimen, which is usually 500 mg two to three
times daily with a maximum total daily dose of 1500 mg.
Little difference in acute or chronic pain relief has been
demonstrated between traditional NSAIDs, such as
naproxen, and COX-2 selective NSAIDs (coxibs) [11, 12].
However, many of the studies comparing the efficacy of
traditional NSAIDs and coxibs were inadequately powered
to detect small differences between the compounds, should
they exist [13]. In contrast, a recent network analysis found
a significant difference between NSAIDs and acet-
aminophen in the treatment of pain in knee and hip
osteoarthritis. The authors concluded that NSAIDs deliv-
ered clinically meaningful pain relief versus placebo but
that acetaminophen has no role in the treatment of
osteoarthritic pain [14].
2 Clinical Pharmacology of NSAIDs
2.1 Pharmacodynamics of NSAIDs
The major mechanism of action of NSAIDs is the blockage
of prostanoid biosynthesis via inhibition of prostaglandin
G/H synthase or COX [13]. COX-1 and COX-2 isoforms
catalyze the initial steps of conversion of free arachidonic
acid (AA) to prostaglandins with roles in nociception,
hypothalamic regulation of body temperature, inflamma-
tion, hemostasis, and cardiovascular function. The most
common adverse effects of NSAIDs are also largely
mediated through effects on the production of prostanoids,
e.g., maintaining gastrointestinal and renal homeostasis.
Despite similarities between the structure and function
of COX-1 and COX-2, they each play different roles in the
body [15]. The role of COX-1 is to maintain a basal rate of
prostanoid biosynthesis [13], including the constitutive
synthesis of prostaglandin (PG)-E2 by the gastrointestinal
tract to mediate gastro-protection from stomach acid and
maintain gastrointestinal homeostasis, and generation of
thromboxane A2 (TXA2) by activated platelets in response
to injury [12, 15]. In contrast, COX-2 activation is involved
in the production of prostanoids in response to inflamma-
tory mediators [16, 17] and in vasoprotection [12, 18].
2.2 Differences in COX-2 Selectivity
NSAIDs are often categorized as non-selective or selec-
tive NSAIDs based on COX inhibition. The non-selective
NSAIDs, also referred to as traditional NSAIDs
(tNSAIDs), inhibit both COX-1 and COX-2 enzymes;
naproxen, diclofenac, and ibuprofen are some examples of
non-selective NSAIDs (Fig. 1). The relative specificity for
COX-1 varies among non-selective NSAIDs. The selec-
tive COX-2 inhibitors (also referred to as coxibs), such as
celecoxib, lumiracoxib, and etoricoxib, selectively inhibit
the COX-2 enzyme with low degrees of COX-1 inhibi-
tion. Since COX-1 activity promotes platelet aggregation,
selective COX-2 inhibitors do not have antiplatelet
effects.
Naproxen binds reversibly with COX-1 and COX-2 to
exert its effects but has an increased selectivity for
COX-1 inhibition, which is fivefold greater than the
level of COX-2 inhibition [19]. Naproxen reaches peak
plasma concentrations (Cmax) between 2 and 4 h
(naproxen sodium Cmax at 1–2 h) and has a half-life of
12–17 h [20]. Naproxen is a highly effective analgesic,
and its long half-life provides consistent blood levels and
Fig. 3 Annual absolute effects
per 1000 of cyclooxygenase-2-
selective non-steroidal anti-
inflammatory drugs (NSAIDs)
and traditional tNSAIDs at
different baseline risks of major
vascular events. For each drug
category, the predicted annual
absolute risks of major vascular
events (±1 standard error) are
shown for patients with
predicted risk of 2.0 % (high
risk) or 0.5 % (low risk) per
annum of a major vascular
event. Data from the CNT meta-
analysis [68]. SE standard error
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efficacy, making it a choice comparator in many clinical
trials.
The localized distribution of NSAIDs in injured tissues
is necessary for maximizing therapeutic activity and low-
ering risks of side effects [21, 22]. NSAIDs can be cate-
gorized as acidic or non-acidic, with acidity affecting
distribution of the drug. NSAIDs that are acidic (e.g.,
diclofenac, ibuprofen, ketoprofen) and have a high affinity
for protein binding selectively accumulate at sites of
inflammation [21–24], while non-acidic NSAIDs (e.g.,
celecoxib, rofecoxib) tend towards homogenous distribu-
tion throughout the body [21]. Naproxen, with a pKa of
4.15, falls into the acidic category [25]. These fundamental
properties at least partially contribute to the effectiveness
and tolerability of naproxen in the treatment of arthritis.
2.3 Implications for Cardiovascular Safety
Both COX-1 and COX-2 isozymes play an important role
in the regulation of vascular homeostasis.
Platelets are an integral component of cardiovascular
hemostasis and express only COX-1, in contrast to
endothelial cells, which express both COX-1 and COX-2.
COX-1 drives production of TXA2, which causes platelet
aggregation, vasoconstriction, and an increase in vascular
and cardiac remodeling. Thromboxanes increase the risk of
cardiovascular events when their activity level is enhanced
[26]. Thus, inhibition of COX-1 mitigates production of
TXA2, potentially lowering the risk of cardiovascular
events.
Differential inhibition of COX isozymes is hypothesized
to be the main driver of the cardiovascular safety of
NSAIDs, with greater COX-2 selectivity correlated with
greater cardiovascular risk [27]. However, this correlation
does not appear to be a direct correlation that can be
identified by rank ordering based on COX-2 selectivity
[28] (Fig. 2). This effect seems to at least partially depend
upon the degree of platelet COX-1 inhibition, in combi-
nation with dosing interval and half-life [29]. Furthermore,
the methodology used to determine COX isozyme selec-
tivity influences interpretation of rank ordering and the
estimation of a correlation with observed cardiovascular
risk [30]. Additionally, other drug-specific effects are
hypothesized to contribute, such as endothelial function
and renal effects [28]. Future studies in the field will pro-
vide a better understanding of drug-specific aspects that
affect cardiovascular safety other than COX selectivity.
For the majority of non-aspirin tNSAIDs, the inhibition
of COX-1 is transient and insufficient to inhibit platelet
activation [31]. The exception is naproxen, which pos-
sesses a long half-life and, at high doses, strongly inhibits
platelet COX-1 activity to prevent platelet aggregation
[32, 33]. Furthermore, the ability of naproxen to inhibit
thromboxane production and platelet aggregation with
standard dosing may contribute to its better safety profile
[34]. In contrast to aspirin’s irreversible modification of
COX-1, naproxen is a reversible inhibitor of COX-1 [33].
COX-2 drives production of PGI2, which plays a car-
dioprotective role in the circulatory system, promotes
vasodilation, and is a potent inhibitor of platelet aggrega-
tion and cell adhesion [31, 35, 36]. This activity is partially
mediated via indirect antagonism towards the activity of
thromboxanes, including TXA2. Therefore, inhibition of
COX-2 is hypothesized to tip the natural balance between
prothrombotic TXA2 and anti-inflammatory prostacyclin
(PGI2), negating the cardioprotective effect of PGI2 [37].
However, a more recent investigation by Kirkby et al. [38].
did not find a role for COX-2 in prostacyclin production in
the cardiovascular system, raising uncertainty about this
hypothesis.
The cardiovascular system shares a major homeostasis
mechanism with the kidneys: maintaining blood pres-
sure. All NSAIDs can attenuate renal function via inhi-
bition of COX-1 and/or COX-2 expressed in the kidneys
[39]. It has been hypothesized that the observed increase
in cardiovascular risk among NSAID users is due to
increased blood pressure via COX-2 inhibition in the
kidneys—an effect not observed with OTC doses [40].
Naproxen does not significantly increase systolic blood
pressure, and this may contribute to its better safety
profile [28, 41].
Fig. 4 Rate ratios and 95 % confidence intervals for major vascular
events due to non-steroidal anti-inflammatory drugs. Data from the
CNT meta-analysis [68] and McGettigan and Henry [67] meta-
analysis
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3 Aspirin Interaction
3.1 Non-Selective NSAIDs and Antiplatelet Effect
of Aspirin
Concomitant use of low-dose aspirin for the prevention of
cardiovascular events is frequent in patients taking
NSAIDs for anti-inflammatory and analgesic effects [13],
particularly in elderly patients with joint pain who may also
be at increased cardiovascular risk. The co-administration
of tNSAIDs, such as ibuprofen, but not coxibs, with low-
dose aspirin has been shown to interfere with the anti-
platelet effect of aspirin [42–46].
3.2 Naproxen and Aspirin
As noted, the majority of the NSAIDs, including naproxen,
act as reversible competitive inhibitors of COX, and the
duration of action for these non-selective NSAIDs is pri-
marily related to their pharmacokinetic clearance [19]. In
contrast, aspirin irreversibly inhibits COX-1 [47].
Naproxen is longer acting than most other tNSAIDs, with a
plasma elimination half-life of 12–17 h [20].
A small study in healthy subjects found a single high
dose of naproxen sodium 1000 mg reduced platelet
aggregation in 60 % of cases after 24 h [48]. Furthermore,
another study found that, while sequential dosing of
naproxen sodium 220 mg twice daily and low-dose aspirin
interfered with the irreversible inhibition of platelet COX-1
afforded by aspirin, the interaction was minimized when
naproxen sodium was given 2 h after low-dose immediate-
release aspirin [46]. However, based on this interaction, the
impact of co-administration with aspirin still needs to be
considered when seeking to understand the cardiovascular
risk of naproxen. The potential for interaction between
naproxen and aspirin depends on both the dose and the
dosing schedule.
A recently completed study examined the impact of
naproxen on serum thromboxane inhibition when added to
aspirin therapy versus aspirin therapy alone (clinicaltri-
als.gov NCT02229461). The results of this study will
provide further insights into whether OTC dosing regimens
of naproxen can maintain sufficient inhibition of throm-
boxane B2 (TXB2) and platelet aggregation when added to
an aspirin regimen at steady state.
3.3 Clinical Significance of Aspirin Interaction
3.3.1 NSAIDs Generally
Currently, the scientific literature has identified no ‘gold
standard’ that defines the percent inhibition of serum
thromboxane sufficient to achieve clinical benefit of pla-
telet inhibition-derived prevention of secondary cardio-
vascular events. There is no conclusive demonstration in
the published literature regarding the appropriate threshold
for serum TXB2 inhibition that would result in clinically
meaningful differences in the prevention of cardiovascular
events such as stroke and MI.
Nevertheless, it is relatively understood that near-com-
plete suppression of serum thromboxane is considered
important for cardioprotection in people receiving low-
dose aspirin, with observed TXB2 inhibition ranging from
95 to 99.5 % [32, 49–52].
In a real-world setting, it is difficult to infer the clinical
impact of these interactions on the typical patient receiving
NSAIDs because of the wide variability of these patients,
including their medical background, and the lack of out-
come data.
3.3.2 Naproxen Specifically
In its entirety, the data suggest that naproxen can interfere
with the TXB2 inhibition provided by aspirin. However,
there is no evidence that a single-day co-administration of
an OTC naproxen dose and aspirin interferes with the
antiplatelet effect of aspirin in a clinically meaningful way.
In fact, when immediate-release aspirin is taken at least 2 h
before naproxen, the TXB2 inhibition is barely impacted
[46]. Nevertheless, the clinical relevance of the apparent
interaction of naproxen/aspirin co-administration is yet to
be established, primarily because real-life use of these
drugs can stray far from the ‘ideal’ and controlled admin-




There are some indicators that NSAIDs may differentially
increase thrombotic risk in patients commensurate with
Fig. 5 Rate ratios and 95 % confidence intervals for myocardial
infarction or coronary heart disease death due to non-steroidal anti-
inflammatory drug. Data from the CNT meta-analysis [68]
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levels of cardiovascular basal risk: evaluating outcomes on
the basis of the patient’s basal risk demonstrates that the
predicted risk for cardiovascular events increased dispro-
portionately more in high-risk patients than in low-risk
patients, particularly with coxibs and diclofenac
[53] (Fig. 3). This further supports the hypothesis that the
differential increase in risk between NSAIDs correlates
most strongly with COX-2 selectivity.
Thus, in retrospect, it should come as no surprise that an
increased incidence of thrombotic events was observed
with the COX-2 inhibitors celecoxib, rofecoxib, and
valdecoxib in randomized placebo-controlled trials
[54–56]. This observation initiated further review into the
cardiovascular effects associated with NSAIDs. Impor-
tantly, the results of observational studies [29, 57, 58], a
network meta-analysis [28], and two meta-analyses of data
derived from randomized controlled trials (RCTs) of an
NSAID versus placebo or an NSAID regimen versus
another NSAID regimen have confirmed the initial obser-
vation of a cardiovascular risk with coxibs but also
extended the concern to use of certain tNSAIDs [13, 59].
Additionally, a recent very large population-based case–
control study found that the use of diclofenac, ibuprofen,
rofecoxib, celecoxib, and meloxicam all significantly
increased the risk of venous thromboembolism in patients
with knee osteoarthritis, whereas the effects of naproxen
use was indistinguishable from those of no NSAID use
[60].
While much of the data suggest that rank ordering of the
varying NSAID compounds with relation to cardiovascular
risk is difficult, the balance of evidence suggests that
naproxen results in a low cardiovascular risk level amongst
NSAIDs, or possibly even neutral cardiovascular risk
levels (i.e., equivalent to placebo). Two large prospective
studies comparing coxibs and naproxen (ADAPT [Alz-
heimer’s Disease Anti-inflammatory Prevention Trial] and
TARGET [Therapeutic Arthritis Research and Gastroin-
testinal Event Trial]) observed different cardiovascular risk
profiles for naproxen versus coxibs, with TARGET
demonstrating a numeric (but non-significant) decrease for
naproxen (hazard ratio [HR] 1.46 for lumiracoxib vs.
naproxen, 95 % confidence interval [CI] 0.89–2.37), and
ADAPT suggestive of increased risk for naproxen (HR
1.63, 95 % CI 1.04–2.55) [61, 62]. An additional trial
(SCOT [Standard Care versus Celecoxib Outcome Trial])
has yielded only topline results, but these preliminary
findings are consistent with the totality of evidence. SCOT
demonstrated no significant difference between celecoxib
and tNSAIDs (grouped together): cardiovascular outcomes
occurred in 1.8 % of the celecoxib arm and 2.2 % of the
tNSAID arm (HR 1.12; p = 0.50). However, although
serious adverse events occurred at a similar rate (5.2 % in
the celecoxib arm vs. 5.8 % in the tNSAID arm), the
celecoxib arm exhibited a significantly greater number of
non-serious adverse events than the tNSAID arm (22 vs.
16.1 %; p\ 0.001), and significantly more patients with-
drew from the celecoxib treatment arm than from the
tNSAID treatment arm (50.9 vs. 30.2 %; p\ 0.0001) [63].
While the SCOT trial contributed to the vast body of
knowledge on NSAIDs and cardiovascular risk, it could
have been potentially more informative to have included a
third placebo-controlled arm to understand baseline risk.
Lastly, the APPROVe (Adenomatous Polyp Prevention on
Vioxx) study compared the COX-2 selective rofecoxib
with placebo and was terminated early due to a signal of
increased cardiovascular adverse events [64].
Based on these clinical studies, which should carry more
weight than observational studies, there is little evidence of
a statistically significant increase in cardiovascular risk in
either the naproxen (where applicable) or pooled tNSAID
treatment groups. The only statistically significant results
were reported in the TARGET naproxen sub-study and
ADAPT. The TARGET sub-study demonstrated that
naproxen had a lower risk of the composite cardiovascular
outcome than did lumiracoxib in patients with
osteoarthritis and a high baseline cardiovascular risk who
are not receiving aspirin [65], while limited post hoc
analyses of ADAPT identified an increased risk in a
composite cardiovascular endpoint for naproxen compared
with placebo.
Of course, with dozens of prospective and observational
studies having been conducted, it is not unexpected that a
few yield contrary results. However, these studies do not
alter the balance of data, as is demonstrated in the
numerous meta-analyses discussed above, especially the
CNT (Coxib and traditional NSAID Trialists’) collabora-
tion and McGettigan meta-analyses, which suggest that
naproxen is not associated with an increased risk of car-
diovascular thrombotic events [66–68] (Figs. 4 and 5). The
more recent CNT meta-analysis observed that major vas-
cular events are increased, by varying degrees, through the
use of NSAIDs. The use of coxibs or diclofenac signifi-
cantly increased major vascular events, major coronary
events, and risk of vascular death. Ibuprofen use
Fig. 6 Rate ratios and 95 % confidence intervals for hospitalizations
for congestive heart failure due to non-steroidal anti-inflammatory
drugs. Data from the CNT meta-analysis [68]
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significantly increased major coronary events but did not
significantly increase risk of vascular death or major vas-
cular events. Naproxen use did not significantly increase
the risk of major vascular events and did not result in an
increased risk of vascular death [68].
The PRECISION trial will provide additional data
regarding the cardiovascular risk of celecoxib compared
with ibuprofen and naproxen [69, 70]. However, it is
unclear (because of the limitations of PRECISION) whe-
ther it will impact the totality of the evidence reviewed in
the CNT meta-analysis. In fact, the equipoise of the
PRECISION trial was questioned by the FDA as a body of
evidence indicates that naproxen exhibits a lower cardio-
vascular risk than other NSAIDs [71]. It should be noted
that both PRECISION [72] and SCOT have limitations: the
results of both trials will only be directly applicable to
prescription dosing regimens (not OTC dosing regimens),
aspirin interactions could undermine the interpretability of
PRECISION results, and SCOT will be underpowered to
provide insight into specific tNSAIDs. Furthermore, cele-
coxib exposure in the SCOT trial was lower than that in
trials in which a cardiovascular risk was observed, sup-
porting the general recommendation that a reduction in
NSAID exposure results in a reduction in cardiovascular
risk. This, of course, is applicable to all NSAIDs, including
naproxen [29].
It is due to this totality of evidence of differential safety
of naproxen with regard to cardiovascular outcomes that
the American Heart Association and American College of
Gastroenterology have issued the recommendations that
naproxen should be the NSAID of choice for patients with
high cardiovascular risk [73–76].
4.2 Hypertension
All NSAIDs, to some degree, alter vasodilation and sodium
excretion by affecting prostanoid production (e.g., PGE2),
which can result in hypertension, a risk factor for cere-
brovascular and thromboembolic events [11, 77–79]. The
COX isozymes are present in various tissues throughout the
body and also affect hemostasis differently via prostanoids
[80, 81]. Platelets are an integral component of cardio-
vascular hemostasis and express only COX-1, in contrast to
endothelial cells, which express both COX-1 and COX-2.
COX-1 drives production of TXA2, which causes platelet
aggregation, vasoconstriction, and an increase in vascular
and cardiac remodeling. COX-2 is necessary for the pro-
duction of prostacyclin, which is a potent vasodilator,
inhibiting platelet function and promoting renal sodium
excretion [29, 73].
It has been hypothesized that an increased cardiovas-
cular risk from NSAID use is due to an increase in blood
pressure as a result of COX-2 inhibition in the kidneys and
alteration of sodium and fluid retention [11, 49, 82]. The
observed increase in blood pressure during long-term
NSAID use is hypothesized to increase cardiovascular risk,
as hypertension is a well-known risk factor for cardiovas-
cular disease. This increased risk would essentially be
associated with chronic exposure. Therefore, one would
hypothesize that the risk would be directly related to
increased blood pressure. However, data are limited on
blood pressure changes due specifically to naproxen use
and associated changes in resultant cardiac ischemic
events; most of the data concern NSAIDs as a class.
An RCT [83], a large meta-analysis [84], and a sys-
tematic review of RCTs [85] all found small and occa-
sionally significant increases in blood pressure due to
prescription dose NSAID use. Given these data, it is not
unexpected that some trials observed an increased risk of
drug–drug interactions when prescription-strength
tNSAIDs and antihypertensives were co-administered over
a period of several weeks [86–88]. In contrast, short-term
exposure to low doses of tNSAIDs (e.g., naproxen or
ibuprofen) has not been shown to affect blood pressure or
demonstrate any meaningful interaction with antihyper-
tensive drugs, and it is not likely to increase the risk of
cardiovascular events according to that mechanism
[40, 88–90], whereas chronic exposure to NSAIDs in
patients with hypertension does increase cardiac ischemic
events [91]. This is reflected in the current class label.
Naproxen was observed to have the least risk among
common NSAIDs for cardiovascular-related events and
deaths, and the fact that it does not substantially increase
systolic blood pressure may play a major role in its
better safety profile [28, 41]. Also, the ability of
naproxen to inhibit thromboxane production and platelet
aggregation may lend further support to the better safety
profile [34]. Thus, the data should be regarded in the
context of the overwhelming body of data suggesting
that naproxen has a neutral cardiovascular adverse event
profile.
4.3 Congestive Heart Failure
Although the focus of NSAID safety with regard to car-
diovascular risk has primarily been on increased throm-
boembolic risk, NSAIDs have also been implicated in fluid
retention and worsening of heart failure via activity on
renal function and the regulation of fluid balance [92].
Inhibition of COX-2 by NSAIDs, and the subsequent
decrease in PGI2 and PGE2 in the renal cortex and juxta-
glomerular cells, can result in a decrease in both renal
blood flow and glomerular filtration rate [93]. There is also
some evidence that NSAIDs inhibit aldosterone metabo-
lism, with potential impacts on fluid retention, blood
pressure, and cardiovascular remodeling [94]. Fluid
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retention is associated with worsening of heart failure in at-
risk patients, especially the elderly [95].
Clinical trials are typically the most robust evidence of
drug associations to outcomes. However, the two clinical
studies published after 2005 reporting congestive heart
failure (CHF) safety data during naproxen use provide no
statistically significant confirmation of an increased risk of
CHF in the naproxen treatment groups [61, 62]. Both
studies were limited in their design for measuring CHF
outcomes.
Since more observational studies have been conducted
in the post-marketing period than clinical studies, they are
a primary source for detecting safety signals on the real-
world use of naproxen, despite their inherent limitations
(retrospective design, selection bias, and confounding
factors). Individually, these studies show no evidence of an
increased CHF risk in patients exposed to naproxen at
either low or high doses [95, 96].
As the number of studies primarily designed to assess
the safety of naproxen with respect to the risk of devel-
opment or progression of CHF is limited, the CNT meta-
analysis provides insight. The authors included RCTs
published after 2005 and reported that any NSAID use does
increase the risk of CHF-related hospital admissions but
that COX-2-selective inhibitors and ibuprofen use are
associated with the highest risk, whereas naproxen was
associated with a lower, albeit nonsignificant, risk in
comparison [97] (Fig. 6).
5 Conclusions
The totality of evidence suggests that while NSAIDs (both
tNSAIDs and COX-2-selective NSAIDs) likely increase
the risk of cardiovascular events, they do so to varying
degrees. This differential increase in risk is hypothesized to
correlate with COX-2 selectivity, although that correlation
does not appear to be the sole determinant of cardiovas-
cular risk. Thus, it is unsurprising that naproxen, which has
low COX-2 selectivity, has been consistently observed to
possess a low, or possibly even neutral, cardiovascular risk
compared with other NSAIDs. Furthermore, risk may be
mitigated through lower doses or shorter duration of use,
such as that with OTC naproxen.
While emerging data are still to be considered for
naproxen—including the SCOT and PRECISION trials—
these studies are unlikely to significantly sway the totality
of the evidence. Both trials examine prescription doses of
NSAIDs, SCOT is underpowered to draw conclusions
about individual tNSAIDs, and the interpretability of
PRECISION could be undermined by aspirin interactions.
New studies are unlikely to alter the benefit–risk assess-
ment of OTC analgesics.
OTC naproxen is an appropriate pain reliever for indi-
viduals with minor aches and pains seeking self-medication.
However, healthcare professionals and patients should
receive proper education regarding the benefits and risks of
naproxen and other NSAIDs, particularly in individuals who
are, or may be, susceptible to cardiovascular side effects, to
make the best treatment decision for a particular individual.
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